Prevention of CMV Disease in Transplantation:
Resistance was studied by genotypic analysis of CMV in PMNL samples collected i) on Day 100 (end of
study drug prophylaxis) and ii) in cases of suspected CMV disease up to 6 months after transplantation.
From the 245 patients randomised to receive valganciclovir, 198 Day 100 samples were available for
testing and no ganciclovir resistance mutations were observed. This compares with 2 ganciclovir
resistance mutations detected in the 103 samples tested (1.9%) for patients in the oral ganciclovir
comparator arm.
Of the 245 patients randomised to receive valganciclovir, samples from 50 patients with suspected CMV
disease were tested and no resistance mutations were observed. Of the 127 patients randomised on the
ganciclovir comparator arm, samples from the 29 patients with suspected CMV disease were tested, from
which two resistance mutations were observed, giving an incidence of resistance of 6.9%.
I found this about valcyte resistance, interesting?
http://www.roche-australia.com/fmfiles/re7229005/downloads/anti-virals/valcyte-pi.pdf